Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01272037
First received: January 6, 2011
Last updated: December 8, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: February 2022 (Final data collection date for primary outcome measure)